Everolimus for the treatment of pancreatic neuroendocrine tumors.


INTRODUCTION Pancreatic neuroendocrine tumors (PNET) represent the second most common primary malignancy of the pancreas. Until recently, therapeutic options for advanced PNET have been limited. AREAS COVERED A recently published Phase III clinical trial demonstrated striking therapeutic activity of the mTOR inhibitor everolimus in advanced PNET and led… (More)
DOI: 10.1517/14656566.2012.713348


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics